Stay updated with breaking news from Mced. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
After years of battling to retain its hold on Grail Inc., Illumina Inc. finally announced that it will be unwinding the ill-fated acquisition of the multi-cancer early detection test maker. In addition to stiff opposition from activist investor Carl Icahn that cost Illumina’s previous CEO and board chair their positions, European and U.S. regulators have consistently opposed the deal. ....
Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection. ....
1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2. Patients in the true-positive group underwent more procedures and surgeries compared to those in the false-positive group. Evidence Rating Level: 2 (Good) Study Rundown: Cancer is a leading cause of death worldwide with nearly two million new cases expected to be diagnosed ....
Explore critical issues surrounding health disparities in cancer screening, as discussed by experts, and the urgent need to bridge gaps in access, trust, and follow-up care for underserved populations. ....
A panel of esteemed cancer experts explore the challenges and opportunities in cancer screening and identification, shedding light on the evolving landscape and its impact on clinical practice. ....